AstraZeneca has surpassed market expectations with its Q3 earnings, raising its 2024 outlook due to strong demand for cancer treatments. The company reported a 20% increase in core earnings per share and a 22% rise in oncology sales. CEO Pascal Soriot expressed optimism about growth continuing through 2025. However, concerns over legal issues in China, including an investigation into China President Leon Wang, have led to a significant drop in share prices despite overall positive earnings. Teljes cikk (Euronews.com)